Abstract | OBJECTIVE: DESIGN: PARTICIPANTS: 1617 men randomised to dutasteride or placebo with a prostate size >40 mL and baseline International Prostate Symptom Score (IPSS) <8. Subjects who took medications for benign prostatic hyperplasia were excluded at study entry. INTERVENTIONS: MAIN OUTCOME MEASURES: RESULTS: LIMITATIONS: Further prospective studies may be warranted to demonstrate generalisability of these results. CONCLUSIONS:
|
Authors | Paul Toren, David Margel, Girish Kulkarni, Antonio Finelli, Alexandre Zlotta, Neil Fleshner |
Journal | BMJ (Clinical research ed.)
(BMJ)
Vol. 346
Pg. f2109
(Apr 15 2013)
ISSN: 1756-1833 [Electronic] England |
PMID | 23587564
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- 5-alpha Reductase Inhibitors
- Azasteroids
- Prostate-Specific Antigen
- Dutasteride
|
Topics |
- 5-alpha Reductase Inhibitors
(administration & dosage, adverse effects)
- Aged
- Asymptomatic Diseases
- Azasteroids
(administration & dosage, adverse effects)
- Disease Progression
- Double-Blind Method
- Drug Monitoring
(methods)
- Dutasteride
- Erectile Dysfunction
(chemically induced)
- Humans
- Male
- Middle Aged
- Prostate
(drug effects, pathology)
- Prostate-Specific Antigen
(blood)
- Prostatic Hyperplasia
(blood, complications, diagnosis, drug therapy, physiopathology)
- Regression Analysis
- Risk Assessment
- Treatment Outcome
- Urinary Retention
(etiology, physiopathology, prevention & control)
- Urinary Tract Infections
(etiology, physiopathology, prevention & control)
|